Tevard Biosciences Appoints Dr. Elisabeth Gardiner as Chief Scientific Officer to Advance tRNA-Based Therapies
TL;DR
Tevard Biosciences appoints Dr. Elisabeth Gardiner as CSO to accelerate the development of tRNA-based therapies, offering a competitive edge in treating genetic diseases.
Tevard Biosciences' engineered suppressor tRNAs precisely correct nonsense mutations, demonstrating sustained protein restoration in Duchenne Muscular Dystrophy models with no adverse effects.
Tevard Biosciences' tRNA-based therapies aim to cure genetic diseases, promising a better future for patients with conditions previously deemed untreatable.
Discover how Tevard Biosciences' innovative tRNA technology is revolutionizing the treatment of genetic diseases by restoring full-length proteins in preclinical models.
Found this article helpful?
Share it with your network and spread the knowledge!
Tevard Biosciences, Inc., a biotechnology firm at the forefront of developing tRNA-based therapies for genetic diseases, has announced the appointment of Dr. Elisabeth Gardiner as its Chief Scientific Officer. With over 25 years of experience in drug discovery and development, Dr. Gardiner's leadership is expected to propel Tevard's innovative suppressor tRNA platform forward, aiming to address the root causes of genetic disorders.
Dr. Gardiner's appointment comes at a pivotal time for Tevard, following promising preclinical results where their tRNA-based therapy restored dystrophin protein expression in a Duchenne Muscular Dystrophy (DMD) model. This breakthrough underscores the potential of tRNA therapies to offer durable solutions for diseases that have been challenging to treat with conventional gene therapy methods.
Daniel Fischer, Co-Founder, President, and CEO of Tevard Biosciences, emphasized Dr. Gardiner's unique combination of scientific expertise and leadership skills as key to advancing the company's pipeline, including its lead program targeting TTN-related dilated cardiomyopathy and ongoing work in Dravet syndrome and other developmental and epileptic encephalopathies.
Dr. Gardiner expressed enthusiasm about joining Tevard, citing the company's innovative approach to tackling rare diseases through its suppressor tRNA platform. Unlike traditional gene therapies, Tevard's method allows for precise protein restoration without the limitations associated with large gene delivery or the need to correct multiple mutations, offering hope for patients with conditions previously deemed untreatable.
The advancement of Tevard's tRNA-based therapies represents a significant leap forward in the treatment of genetic diseases, with the potential to transform the lives of patients worldwide. As the company moves its lead programs toward clinical trials, the scientific and medical communities will be watching closely for the next developments in this promising field.
Curated from Reportable
